Pipeline

Symberix is advancing a portfolio of first-in-class drug candidates for multiple adjunct and monotherapeutic indications. Our discovery platform enables precise targeting of bacteria implicated in intestinal toxicity and gastrointestinal disease. By identifying specific bacterial enzyme targets, we can develop small molecule drugs to block harmful bacterial activity without disrupting the innocuous endogenous microbiota.